In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.
Our reports have been used by over 10K customers, including:
‘Gene and Cell Therapies targeting CNS Disorders – Market Insights and Market Forecast – 2026’ report delivers an in-depth understanding of the market trends of Gene and Cell Therapies targeting CNS Disorders in in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Gene and Cell Therapies targeting...
Giving support: Funding increases should help the industry recover from current-year disruption Abstract Learning Disability, Mental Health & Substance Abuse Facilities in the UK Operators in this industry provide residential care for people with learning disabilities, mental illness or substance abuse...
Aiding care: Emergency funding to counteract the effects of COVID-19 is expected to support industry revenue Abstract Domiciliary Care in the UK Companies operating in the Domiciliary Care industry provide intensive, at-home nursing care to patients. Residential nursing care activities are excluded...
The North America Pupillometer Market would witness market growth of 8.4% CAGR during the forecast period (2020-2026). Pupillometry is widely used to measure the dilation of the pupil that is beneficial in understanding situations deviating from normal conditions. Several imaging modalities like magnetic resonance imaging and Computerised...
Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2020
According to the recently published report ’Metabotropic Glutamate Receptor 5 – Pipeline Review, H1 2020’; Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 19 molecules. Out of...
UK Protection Insurance 2019: Critical Illness & Income Protection
This report focuses on the major (and closely related) IP and CI product lines.It examines the market size of both IP and standalone CI products with regards to the changes in new contracts and premiums written.
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2018 Summary Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes....
Diagnostic Imaging Density
Illicit Drug Use
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.